Różnica między Ozempic a Wegovy: dlaczego te dwa leki to nie to samo

Same molecule, different missions: how the licensing split happened

The confusion is understandable. Semaglutide is one compound made by Novo Nordisk, yet it reaches the market as two separately authorised products. Ozempic came first, approved to lower blood sugar and reduce cardiovascular risk in people with type 2 diabetes. Wegovy followed, authorised at a higher dose for chronic weight management after the STEP trial programme demonstrated significant body-weight reduction. You can read the detail behind each approval on the semaglutide overview page, which covers how the same active substance ended up in two licensed medicines with distinct indications.

This is not a technicality. MHRA authorisation defines what a medicine can legally be prescribed for. A GP or online prescriber who issues Ozempic to someone without type 2 diabetes, specifically to help them lose weight, is prescribing outside the product's licence. That does not make off-label prescribing universally impermissible, but it does mean the prescriber takes on significant additional responsibility and must document a clear clinical justification. In routine private weight-loss practice, it simply does not happen, there is a better, more appropriate option available.

The NHS is equally clear on this point, and the question of whether Wegovy and Ozempic are the same medicine is one of the most searched queries on the topic. The short answer: same ingredient, different products, different lawful purposes.

Why the doses matter when you are making a weight-management decision

Dose is where the practical difference becomes clearest. Ozempic is titrated up to 1 mg weekly for most diabetes patients, with a 2 mg option available for those needing tighter glycaemic control. Wegovy's maintenance pathway climbs to 2.4 mg weekly, a meaningfully higher exposure to semaglutide, which is why the STEP 1 trial recorded around 15% average body-weight reduction at that dose over 68 weeks. The MHRA has since approved a 7.2 mg single-dose pen for Wegovy, specifically for adults with obesity (BMI 30 or above), taking the ceiling higher still.

That dose difference is not arbitrary. The clinical trials that established efficacy for weight management were run at Wegovy's dose range, not Ozempic's. Using Ozempic doses to pursue weight loss would not replicate those results, and the data supporting them would not apply. Understanding how Ozempic and Wegovy work on the GLP-1 receptor helps explain why dose and indication are inseparable, the appetite-related effects are dose-dependent.

If you are curious how quickly the weight-loss effect can become apparent on the licensed product, the evidence on when weight loss typically begins with Wegovy is worth reading before any consultation.

What is actually licensed for weight loss in the UK, and where Mounjaro fits

In the UK, two injectable medicines are currently licensed specifically for weight management: Wegovy (semaglutide) and Mounjaro (tirzepatide). Ozempic is not one of them. Neither is Rybelsus, the oral semaglutide tablet licensed for type 2 diabetes, a distinction that parallels the Ozempic situation exactly.

Wegovy and Mounjaro work through related but different pathways. Wegovy acts on the GLP-1 receptor alone. Mounjaro activates both the GLP-1 and GIP receptors, making it the only dual-agonist weight-loss medicine licensed in the UK. In the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks. The Wegovy treatment page covers how Wegovy is prescribed in practice, while the weight-loss treatment overview sets out both options side by side.

Both medicines are prescription-only under UK law, which means neither can be dispensed without a clinical assessment. The NHS's own guidance on semaglutide covers the licensed indications clearly, and NICE's appraisal of semaglutide for weight management (TA875) details the evidence base that led to Wegovy's recommendation within specialist services.

Choosing between Wegovy and Mounjaro: a clinical decision, not a shopping one

People who arrive at this question (Ozempic versus Wegovy) often get there because Ozempic has dominated headlines and social media in a way that the weight-loss-licensed products have not yet matched. The practical upshot is that if you do not have type 2 diabetes, Ozempic is not the route. Wegovy and Mounjaro are.

Which of those two suits you is a question a prescriber answers after reviewing your health history, current medications, BMI, and any relevant conditions. There is no universal answer. Cost is a factor too; the Wegovy price comparison page gives an honest picture of what private treatment currently costs in the UK, without hiding the Lilly price increase that reshaped the market from September 2025.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally. Your pen, once approved, is dispatched the same day if you order before midday on a working day, arriving with DPD the next working day, in plain, unmarked packaging. That is the standard, not a selling point. If you want to understand who oversees that clinical process, the clinical team profile is there to read. For anything less clear-cut, the FAQs cover the most common questions our prescribers are asked.